methionine sulfoxide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-11-09. Anything still debated is marked as such rather than presented as settled.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
溶液状态的稳定性明显低于冻干粉。肽类在水溶液中可能经历水解、氧化与聚集，其中甲硫氨酸和天冬酰胺等残基常是敏感位点。Semax 含有甲硫氨酸，因此氧化风险相对突出。工作液一般主张现配现用，或冷藏并在数日内用尽。缓冲液种类、pH 和离子强度都会影响降解速率，而关于最佳条件的公开数据并不统一。
常规纯度与身份确认依赖反相高效液相色谱，并辅以质谱测定分子量。氨基酸组成分析可用于验证序列构成，肽图分析则能进一步定位修饰或降解产物。杂质谱通常关注缺失序列肽、截短片段和氧化产物。不同方法的检出限并不相同，因此各实验室报告的纯度数值不宜直接横向比较。
多数实验室与市售的 Semax 以冻干粉形式提供。冻干粉通常建议保存在 -20 °C 或更低温度下，同时避免光照与反复升温。短期运输有时采用冷藏条件，但长期保存仍以冷冻为主。分包操作应尽量减少开盖次数，以降低吸湿和微生物污染的风险。开封后若未一次用完，建议在干燥环境中密封并尽快放回低温储存。
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Contains one methionine sulfur atom |
| Molecular mass | Approximately 814 Da | Consistent with a seven-residue peptide |
| Appearance | White to off-white powder | Typical lyophilized form |
| Solubility | Freely soluble in water | Also soluble in dimethyl sulfoxide |
| Typical storage | -20 °C, desiccated | Limits methionine oxidation |
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.
Dissolution is normally performed in water, phosphate-buffered saline, or normal saline, since the peptide is freely soluble in aqueous media and is rarely handled with strong organic solvents. Solution pH should be kept near neutral, because extreme acidity or alkalinity accelerates backbone hydrolysis and encourages oxidation of the methionine side chain. Once dissolved, the material is less stable than the dry powder and is commonly divided into single-use portions and frozen. Buffers containing primary amines, such as Tris, are often avoided because of possible side reactions.
Purity assessment relies mainly on reversed-phase high-performance liquid chromatography, which separates the target heptapeptide from truncated sequences, deletion analogues, and oxidised forms. Mass spectrometry, usually coupled to liquid chromatography, confirms identity through the expected molecular ion and reveals modifications such as methionine sulfoxide formation. Amino acid analysis can verify composition, and tandem mass spectrometry supports sequence confirmation. Ultraviolet detection near 254 to 280 nanometres is convenient because the phenylalanine and histidine residues absorb in that region. Nuclear magnetic resonance is rarely used for routine release testing.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Published studies are dominated by animal models of stroke, ischemia, and cognitive impairment, with a smaller number of human trials conducted in Russia. Many of the human reports are small, single-center, and published in Russian-language journals, which limits independent scrutiny. Outcome measures vary between studies and often rely on clinician-rated scales rather than objective biomarkers. Systematic reviews have noted the methodological weaknesses and called for larger, preregistered trials before firm conclusions can be drawn.
Claims about enhanced focus, memory, or mood in healthy people rest mostly on anecdotal reports and community discussion rather than on controlled data. It remains unclear whether any cognitive benefit observed in patients recovering from brain injury would extend to uninjured users. Dose-response relationships, long-term safety, and interactions with other drugs are not well characterized in the peer-reviewed literature. Questions about optimal route of administration and treatment duration likewise remain open.
Semax binds to melanocortin receptors and is thought to influence neuronal survival and plasticity rather than to act through the adrenal axis. Laboratory work has shown increased expression of brain-derived neurotrophic factor and nerve growth factor in treated tissue. Changes in c-Fos, a marker of neuronal activation, have also been reported. Because the peptide is rapidly degraded by peptidases, its effects are generally attributed to downstream signaling cascades rather than to sustained receptor occupancy.
Many mixed valence compounds contain both iron(II) and iron(III) centers, such as magnetite and Prussian blue (Fe4[Fe(CN)6]3). The latter is used as the traditional "blue" in blueprints. Iron is the first of the transition metals that cannot reach its group oxidation state of +8, although its heavier congeners ruthenium and osmium can, with ruthenium having more difficulty than osmium. Ruthenium exhibits an aqueous cationic chemistry in its low oxidation states similar to that of iron, but osmium does not, favoring high oxidation states in which it forms anionic complexes. In the second half of the 3d transition series, vertical similarities down the groups compete with the horizontal similarities of iron with its neighbors cobalt and nickel in the periodic table, which are also ferromagnetic at room temperature and share similar chemistry. As such, iron, cobalt, and nickel are sometimes grouped together as the iron triad. Unlike many other metals, iron does not form amalgams with mercury. As a result, mercury is traded in standardized 76 pound flasks (34 kg) made of iron. Iron is by far the most reactive element in its group; it is pyrophoric when finely divided and dissolves easily in dilute acids, giving Fe2+. However, it does not react with concentrated nitric acid and other oxidizing acids due to the formation of an impervious oxide layer, which can nevertheless react with hydrochloric acid. High-purity iron, called electrolytic iron, is considered to be resistant to rust, due to its oxide layer.
, where distance is the direct (not logarithmic) distance in number of decades or "octaves" to the right the mass concentration is found. To translate from mass to molar concentration, the dividend (molar mass and the divisor (1000) in the division change places, or, alternatively, distance to right is changed to distance to left. Substances with a molar mass around 1000g/mol (e.g. thyroxine) are almost vertically aligned in the mass and molar images. Adrenocorticotropic hormone, on the other hand, with a molar mass of 4540, is 0.7 decades to the right in the mass image. Substances with molar mass below 1000g/mol (e.g. electrolytes and metabolites) would have "negative" distance, that is, masses deviating to the left. Many substances given in mass concentration are not given in molar amount because they haven't been added to the article. The diagram above can also be used as an alternative way to convert any substance concentration (not only the normal or optimal ones) from molar to mass units and vice versa for those substances appearing in both scales, by measuring how much they are horizontally displaced from one another (representing the molar mass for that substance), and using the same distance from the concentration to be converted to determine the equivalent concentration in terms of the other unit. For example, on a certain monitor, the horizontal distance between the upper limits for parathyroid hormone in pmol/L and pg/mL may be 7 cm, with the mass concentration to the right.
=== Reproduction === It has been postulated that MCH has a modulatory role with the release of Luteinizing Hormone (LH) either by directly acting on the pituitary gland or indirectly by affecting Gonadotropin-releasing hormone (GNRH) in the hypothalamus. Estrogen seems to be necessary in order for MCH to affect reproduction.
=== Cephadroxil === Cefadroxil is an antibiotic. Bristol-Myers Squibb (BMS) patented the "Bouzard form" under US Patent No. 4,504,657 ('657) in 1985. The patenting took 6 years due to disputes about polymorphs. An earlier patent (US Patent No. 3,781,282) covered a different form, the "Micetich form". Attempts to replicate the Micetich form according to Example 19 in the '282 patent consistently yielded the Bouzard form, leading to challenges that the '657 patent was already inherent in the '282 patent, thus invalidated by prior art. BMS argued that the prevalence of the Bouzard form in manufacturing facilities led to unintentional seeding. Experimental tests of the seeding theory were ambiguous, but eventually the patent was granted. Later, Zenith Laboratories marketed a cefadroxil hemihydrate. BMS sued for "gastrointestinal infringement", claiming it converted to the patented Bouzard form in the stomach. The case hinged on the interpretation of X-ray diffraction data, with BMS arguing it demonstrated the presence of the Bouzard form in patients who ingested Zenith's product. However, the court sided with Zenith.
Sources: en.wikipedia.org
=== Primary packaging === Primary packaging is directly in contact with the food products, creating the ideal headspace for them, while providing protection from external alteration. Additionally, primary packaging, also known as retail packaging or consumer units, is responsible for the marketing aspects of food packaging. Typically, the packaging materials used in the primary level include cardboard cartons, plastic trays, glass bottles and multi-layered structures (Tetra Pak).
=== Beginnings === In September 1935, British chocolate manufacturer Rowntree's brought the first aerated chocolate, Aero, to market. At the time, Rowntree's had been struggling for several years to compete with rival chocolate maker Cadbury's Cadbury Dairy Milk and was looking for a new product to gain an advantage. The new chocolate was the outcome of significant research focused on developing a "count line" chocolate inspired by the recent introduction of the Mars bar to the UK market. Rowntree's patented their aerated chocolate broadly, covering variants such as chocolate with inclusions. As it was released to market, the new chocolate garnered strong sales and positive reviews, although some concerns were voiced within Rowntree's that the product would be a novelty. In their initial marketing, Rowntree's promoted aerated chocolate as better than solid chocolate: more digestible and lacking its "cloying after-taste". Cadbury objected to this and petitioned Rowntree's to stop denigrating rival chocolate makers in marketing.Rival chocolate markers attempted to position their existing product lines as competition (Cadbury their crumbly Flake bars, and Fry's their aerated-honeycomb-filled Crunchie bars), but none were seen by customers as "aerated" in the same sense as Aero. Further to their objections about aerated chocolate's digestibility, Cadbury contested the validity of the patent itself, arguing it overstepped and covered chocolates Cadbury already manufactured, as well as being malformed.
=== EC 2.7.7: Nucleotidyltransferases === EC 2.7.7.1: nicotinamide-nucleotide adenylyltransferase EC 2.7.7.2: FAD synthase EC 2.7.7.3: pantetheine-phosphate adenylyltransferase EC 2.7.7.4: sulfate adenylyltransferase EC 2.7.7.5: sulfate adenylyltransferase (ADP) EC 2.7.7.6: DNA-directed RNA polymerase EC 2.7.7.7: DNA-directed DNA polymerase EC 2.7.7.8: polyribonucleotide nucleotidyltransferase EC 2.7.7.9: UTP—glucose-1-phosphate uridylyltransferase EC 2.7.7.10: UTP—hexose-1-phosphate uridylyltransferase EC 2.7.7.11: UTP—xylose-1-phosphate uridylyltransferase EC 2.7.7.12: UDP-glucose—hexose-1-phosphate uridylyltransferase EC 2.7.7.13: mannose-1-phosphate guanylyltransferase EC 2.7.7.14: ethanolamine-phosphate cytidylyltransferase EC 2.7.7.15: choline-phosphate cytidylyltransferase EC 2.7.7.16: Now EC 4.6.1.18, pancreatic ribonuclease EC 2.7.7.17: Now EC 4.6.1.19, ribonuclease T2 EC 2.7.7.18: nicotinate-nucleotide adenylyltransferase EC 2.7.7.19: polynucleotide adenylyltransferase EC 2.7.7.20: deleted (identical with EC 2.7.7.72, CCA tRNA nucleotidyltransferase EC 2.7.7.21: Now EC 2.7.7.72, CCA tRNA nucleotidyltransferase EC 2.7.7.22: mannose-1-phosphate guanylyltransferase (GDP) EC 2.7.7.23: UDP-N-acetylglucosamine diphosphorylase EC 2.7.7.24: glucose-1-phosphate thymidylyltransferase EC 2.7.7.25: Now EC 2.7.7.72, CCA tRNA nucleotidyltransferase EC 2.7.7.26: Now EC 4.6.1.24, ribonuclease T1 EC 2.7.7.27: glucose-1-phosphate adenylyltransferase EC 2.7.7.28: nucleoside-triphosphate-hexose-1-phosphate nucleotidyltransferase EC 2.7.7.29: identical to EC 2.7.7.28, nucleoside-triphosphate-hexose-1-phosphate nucleotidyltransferase EC 2.7.7.30: fucose-1-phosphate guanylyltransferase EC 2.7.7.31: DNA nucleotidylexotransferase EC 2.7.7.32: galactose-1-phosphate thymidylyltransferase EC 2.7.7.33: glucose-1-phosphate cytidylyltransferase EC 2.7.7.34: glucose-1-phosphate guanylyltransferase EC 2.7.7.35: ribose-5-phosphate adenylyltransferase EC 2.7.7.36: aldose-1-phosphate adenylyltransferase EC 2.7.7.37: aldose-1-phosphate nucleotidyltransferase EC 2.7.7.38: 3-deoxy-manno-octulosonate cytidylyltransferase EC 2.7.7.39: glycerol-3-phosphate cytidylyltransferase EC 2.7.7.40: D-ribitol-5-phosphate cytidylyltransferase EC 2.7.7.41: phosphatidate cytidylyltransferase EC 2.7.7.42: [glutamine synthetase] adenylyltransferase EC 2.7.7.43: N-acylneuraminate cytidylyltransferase EC 2.7.7.44: glucuronate-1-phosphate uridylyltransferase EC 2.7.7.45: guanosine-triphosphate guanylyltransferase EC 2.7.7.46: gentamicin 2′′-nucleotidyltransferase EC 2.7.7.47: streptomycin 3′′-adenylyltransferase EC 2.7.7.48: RNA-directed RNA polymerase EC 2.7.7.49: RNA-directed DNA polymerase EC 2.7.7.50: mRNA guanylyltransferase EC 2.7.7.51: adenylylsulfate—ammonia adenylyltransferase EC 2.7.7.52: RNA uridylyltransferase EC 2.7.7.53: ATP adenylyltransferase EC 2.7.7.54: The activity is part of EC 6.3.2.40, cyclopeptine synthase EC 2.7.7.55: The activity is part of EC 6.3.2.40, cyclopeptine synthase EC 2.7.7.56: tRNA nucleotidyltransferase EC 2.7.7.57: N-methylphosphoethanolamine cytidylyltransferase EC 2.7.7.58: Now included in EC 6.2.1.71, 2,3-dihydroxybenzoate[aryl-carrier protein] ligase EC 2.7.7.59: [protein-PII] uridylyltransferase EC 2.7.7.60: 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase EC 2.7.7.61: citrate lyase holo-[acyl-carrier protein] synthase EC 2.7.7.62: adenosylcobinamide-phosphate guanylyltransferase EC 2.7.7.63: Now EC 6.3.1.20, lipoate—protein ligase EC 2.7.7.64: UTP-monosaccharide-1-phosphate uridylyltransferase EC 2.7.7.65: diguanylate cyclase EC 2.7.7.66: malonate decarboxylase holo-[acyl-carrier protein] synthase EC 2.7.7.67: CDP-2,3-bis-(O-geranylgeranyl)-sn-glycerol synthase EC 2.7.7.68: 2-phospho-L-lactate guanylyltransferase EC 2.7.7.69: GDP-L-galactose/GDP-D-glucose: hexose 1-phosphate guanylyltransferase EC 2.7.7.70: D-glycero-β-D-manno-heptose 1-phosphate adenylyltransferase EC 2.7.7.71: D-glycero-α-D-manno-heptose 1-phosphate guanylyltransferase EC 2.7.7.72: CCA tRNA nucleotidyltransferase EC 2.7.7.73: sulfur carrier protein ThiS adenylyltransferase EC 2.7.7.74: 1L-myo-inositol 1-phosphate cytidylyltransferase EC 2.7.7.75: molybdopterin adenylyltransferase EC 2.7.7.76: molybdenum cofactor cytidylyltransferase EC 2.7.7.77: molybdenum cofactor guanylyltransferase EC 2.7.7.78: GDP-D-glucose phosphorylase EC 2.7.7.79: tRNAHis guanylyltransferase EC 2.7.7.80: molybdopterin-synthase adenylyltransferase EC 2.7.7.81: pseudaminic acid cytidylyltransferase EC 2.7.7.82: CMP-N,N′-diacetyllegionaminic acid synthase EC 2.7.7.83: UDP-N-acetylgalactosamine diphosphorylase EC 2.7.7.84: diadenylate cyclase EC 2.7.7.85: 2′-5′ oligoadenylate synthase EC 2.7.7.86: cyclic GMP-AMP synthase EC 2.7.7.87: L-threonylcarbamoyladenylate synthase EC 2.7.7.88: GDP polyribonucleotidyltransferase EC 2.7.7.89: [glutamine synthetase]-adenylyl-L-tyrosine phosphorylase EC 2.7.7.90: 8-amino-3,8-dideoxy-''manno''-octulosonate cytidylyltransferase EC 2.7.7.91: valienol-1-phosphate guanylyltransferase EC 2.7.7.92: 3-deoxy-D-glycero-D-galacto-nonulopyranosonate cytidylyltransferase EC 2.7.7.93: phosphonoformate cytidylyltransferase EC 2.7.7.94: Now EC 6.2.1.51, 4-hydroxyphenylalkanoate adenylyltransferase FadD29 EC 2.7.7.95: Now EC 6.2.1.49, long-chain fatty acid adenylyltransferase FadD28 EC 2.7.7.96: ADP-D-ribose pyrophosphorylase EC 2.7.7.97: 3-hydroxy-4-methylanthranilate adenylyltransferase EC 2.7.7.98: Now EC 6.2.1.50, 4-hydroxybenzoate adenylyltransferase FadD22 EC 2.7.7.99: N-acetyl-α-D-muramate 1-phosphate uridylyltransferase EC 2.7.7.100: SAMP-activating enzyme EC 2.7.7.101: DNA primase DnaG EC 2.7.7.102: DNA primase AEP EC 2.7.7.103: L-glutamine-phosphate cytidylyltransferase EC 2.7.7.104: 2-hydroxyethylphosphonate cytidylyltransferase EC 2.7.7.105: phospho''enol''pyruvate guanylyltransferase EC 2.7.7.106: 3-phospho-D-glycerate guanylyltransferase
NMR spectroscopy is nucleus specific. Thus, it can distinguish between hydrogen and deuterium. The amide protons in the protein exchange readily with the solvent, and, if the solvent contains a different isotope, typically deuterium, the reaction can be monitored by NMR spectroscopy. How rapidly a given amide exchanges reflects its solvent accessibility. Thus amide exchange rates can give information on which parts of the protein are buried, hydrogen-bonded, etc. A common application is to compare the exchange of a free form versus a complex. The amides that become protected in the complex, are assumed to be in the interaction interface.
In response to shifts in federal policy in the transition between the Biden and Trump administrations, Pritzker signed a number of bills codifying federal labor protections into state law: the Illinois Workers' Rights and Safety Act, which preserves regulations defined by the Occupational Safety and Health Act of 1970, the Fair Labor Standards Act of 1938, and the Federal Coal Mine Health and Safety Act of 1969, regardless of any changes at the federal level; an amendment to the Prevailing Wage Act that ensures that workers for federally funded construction projects administered by the state or local governments are paid the Illinois prevailing wage whenever it is higher than the federal rate; and a bill eliminating references to the Equal Pay Act of 1963 that would have tied some provisions to federal programs, so that federal changes will not undermine the state's requirement that employers with 100 or more employees report on wages by employees' gender and race or ethnicity.
Sources: en.wikipedia.org
Presidential Unit Citation (Army) for Sainte-Mère-Église. Presidential Unit Citation (Army) for Operation Market Garden. Presidential Unit Citation (Army) for Chiunzi Pass/Naples/Foggia awarded to the following units of the 82nd Airborne: 319th Glider Field Artillery Battalion, 307th Engineer Battalion (2nd), 80th Anti-aircraft Battalion and Company H, 504 PIR Presidential Unit Citation (Army) for the Battle of Samawah, April 2003, awarded to the following unit of the 82nd Airborne: 2nd Brigade Combat Team (325th Airborne Infantry Regiment) Presidential Unit Citation (Army) for Operation Turki Bowl, OIF, November 2007, awarded to the following unit of the 82nd Airborne: 5th Squadron, 73rd Cavalry, 3rd Brigade, 505th PIR Valorous Unit Citation (Army) for Operation Iraqi Freedom (3rd Brigade Combat Team, OIF 1) Valorous Unit Citation (Army) for actions on the objective in the Baghdad neighborhood of Ghazaliya. While attached to the 3rd Brigade, 1st Armored Division. Cited in Department of the Army General Order 2009–10 Meritorious Unit Commendation (Army) for Southwest Asia. Superior Unit Award (Army) US Army Garrison, Ft Bragg 11 September 2001 – 15 April 2006 Cited in DAGO 2009–29 French Croix de Guerre with Palm, World War II for Sainte-Mère-Église. French Croix de Guerre with Palm, World War II for Cotentin. French Croix de Guerre, World War II, Fourragère Belgian Fourragere 1940 Cited in the Order of the Day of the Belgian Army for action in the Ardennes Cited in the Order of the Day of the Belgian Army for action in Belgium And Germany.
=== Novels === Amulya Malladi's 2002 novel A Breath of Fresh Air relates the story of a mother and son who develop health issues as a result of exposure to gas at Bhopal. The book is based on Malladi's recollections of Bhopal during the accident. Indra Sinha released Animal's People in 2007. The novel tells the story of a boy who is born with a spinal condition due to effects of the gas. The book was shortlisted for the Man Booker Prize. Arundhati Roy's 2017 novel The Ministry of Utmost Happiness which deals with many contemporary political issues in India, also features several characters still dealing with the aftermath of the gas leak. Annie Murray's novel Mother and Child (2019) is partly set in post-disaster Bhopal.
It remains the deadliest terrorist attack in history, as well as the deadliest incident for firefighters and law enforcement personnel in American history, killing 343 and 72 members, respectively. The crashes of Flight 11 and Flight 175 were the deadliest aviation disasters of all time, and the collision of Flight 77 with the Pentagon resulted in the fourth-highest number of ground fatalities in a plane crash in history. The destruction of the World Trade Center and its environs seriously harmed the U.S. economy and induced global market shocks. Many other countries tightened airport security, strengthened anti-terrorism legislation and expanded their powers of law enforcement and intelligence agencies. The total number of deaths caused by the attacks, combined with the death tolls from the conflicts they directly triggered, has been estimated by the Costs of War Project to be more than 4.5 million. Cleanup of the World Trade Center site (colloquially known as "Ground Zero") was completed in May 2002, while the Pentagon was repaired within a year. After delays in the design of a replacement complex, six new buildings were planned to replace the lost towers at the World Trade Center site, along with a museum and memorial dedicated to those who were killed or injured in the attacks. The tallest building, One World Trade Center, began construction in 2006 and opened in 2014.
=== Mucosal surface delivery === Alternatives included aerosol instillation of naked DNA on mucosal surfaces, such as the nasal and lung mucosa, and topical administration of pDNA to the eye and vaginal mucosa. Mucosal surface delivery has also been achieved using cationic liposome-DNA preparations, biodegradable microspheres, attenuated Salmonalla, Shigella or Listeria vectors for oral administration to the intestinal mucosa and recombinant adenovirus vectors.
== Nutritional value == Lysine is an essential amino acid in humans. The human daily nutritional requirement varies from ~60 mg/kg in infancy to ~30 mg/kg in adults. This requirement is commonly met in a western society with the intake of lysine from meat and vegetable sources well in excess of the recommended requirement. In vegetarian diets, the intake of lysine is less due to the limited quantity of lysine in cereal crops compared to meat sources. Given the limiting concentration of lysine in cereal crops, it has long been speculated that the content of lysine can be increased through genetic modification practices. Often these practices have involved the intentional dysregulation of the DAP pathway by means of introducing lysine feedback-insensitive orthologues of the DHDPS enzyme. These methods have met limited success likely due to the toxic side effects of increased free lysine and indirect effects on the TCA cycle. Plants accumulate lysine and other amino acids in the form of seed storage proteins, found within the seeds of the plant, and this represents the edible component of cereal crops. This highlights the need to not only increase free lysine, but also direct lysine towards the synthesis of stable seed storage proteins, and subsequently, increase the nutritional value of the consumable component of crops.
Sources: en.wikipedia.org
It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.
Most published work uses intranasal administration, matching the route of the registered Russian formulation. Some animal experiments use intravenous or intraperitoneal injection. The route matters because the intact peptide is cleared rapidly from blood, so exposure differs between methods.
A purity value describes the share of the powder accounted for by the target peptide, usually by high-performance liquid chromatography. It does not confirm that the sequence is correct, which requires mass spectrometry or amino acid analysis. Purity and identity are separate checks.
一般不建议常温长期保存。多数说明指向 -20 °C 冷冻避光。常温运输通常被视为短期可接受，但会加快降解风险。